Exogenous gene expression in therapeutic adeno virus to minimize impact to viral kinetics
By using self-cleaving peptides to separate expressions of native and exogenous ORFs in adenoviral vectors, the challenge of limited genome space is addressed, achieving high therapeutic protein expression with maintained viral replication.
Patent Information
- Application Number
- JP2024121060
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-02-23
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing adenoviral vectors face challenges in efficiently incorporating exogenous open reading frames (ORFs) due to limited genome space, leading to impaired viral replication kinetics and protein expression when directly fused with native adenoviral proteins.
Incorporation of a self-cleaving peptide sequence, such as the 2A peptide, between native and exogenous ORFs within the adenoviral genome to facilitate separate expression of proteins, optimizing the placement of exogenous ORFs to maintain viral replication kinetics.
This approach allows for high expression levels of therapeutic proteins while maintaining wild-type viral dynamics, enabling effective therapeutic applications without compromising adenoviral replication.
Smart Images

Figure 2024156764000007 
Figure 2024156764000008 
Figure 2024156764000009
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 298,653, filed February 23, 2016, which is incorporated by reference in its entirety.
[0002] The present disclosure relates to optimal placement of exogenous open reading frames in recombinant adenovirus constructs and therapeutic applications of the recombinant viruses. [Background technology]
[0003] Adenovirus serotype 5 (Ad5) is the vector of choice in basic research applications, mouse lung cancer models, and human gene therapy trials. Adenoviruses have a stable 36 kb double-stranded DNA genome protected by a protein capsid covered with Ad fiber protein spikes that target infection to receptors on specific cell types. Adenoviruses do not integrate into host DNA, can be produced at high titers using established protocols, and have proven safety in human gene therapy and cancer applications. Thus, Ad-based vectors hold great promise in cancer diagnostics and therapeutics. Summary of the Invention [Means for solving the problem]
[0004] The present specification discloses a recombinant adenovirus genome, which comprises a heterologous open reading frame (ORF) and a self-cleaving peptide coding sequence.The heterologous ORF can, for example, code for therapeutic protein.The recombinant adenovirus genome and the recombinant adenovirus produced by the disclosed genome can be used in therapeutic applications, for example, for the treatment of cancer.
[0005] Provided herein is a recombinant adenovirus genome that includes a heterologous ORF and a self-cleaving peptide coding sequence, both in the same reading frame as and operably linked to an endogenous adenovirus ORF, wherein the self-cleaving peptide coding sequence is located between the heterologous ORF and the endogenous ORF. In some embodiments, the endogenous ORF is E1B-55k and the heterologous ORF is 3' of E1B-55k, the endogenous ORF is DNA polymerase and the heterologous ORF is 5' of the DNA polymerase, the endogenous ORF is DNA binding protein (DBP) and the heterologous ORF is 3' of DBP, the endogenous ORF is adenovirus death protein (ADP) and the heterologous ORF is 5' of ADP, the endogenous ORF is E3-14.7k and the heterologous ORF is 3' of E3-14.7k, the endogenous ORF is E4-ORF2 and the heterologous ORF is 5' of E4-ORF2, or the endogenous ORF is fiber and the heterologous ORF is 3' of fiber. In some examples, the heterologous ORF encodes a therapeutic protein.
[0006] Further provided herein is a recombinant adenovirus comprising the recombinant adenovirus genome disclosed herein. Also provided is a composition comprising the recombinant adenovirus genome or recombinant adenovirus disclosed herein and a pharma- ceutically acceptable carrier.
[0007] Also provided are methods of delivering therapeutic proteins to a subject by administering to the subject a recombinant adenoviral genome or recombinant adenovirus (or a composition thereof) disclosed herein, in which the heterologous ORF of the recombinant adenoviral genome or recombinant adenovirus encodes a therapeutic protein.
[0008] Further provided is the method of inhibiting tumor cell viability, inhibiting tumor cell proliferation, inhibiting tumor progression, reducing tumor volume, and treating subjects with cancer by administering recombinant adenovirus genome or recombinant adenovirus (or its composition) disclosed herein.In these methods, the heterologous ORF of recombinant adenovirus genome or recombinant adenovirus codes for therapeutic protein suitable for treating cancer.
[0009] The above and other objects and features of the present disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying drawings. In certain embodiments, for example, the following items are provided: (Item 1) A recombinant adenovirus genome comprising a heterologous open reading frame (ORF) and a self-cleaving peptide coding sequence, both in the same reading frame and operably linked to an endogenous adenovirus ORF, wherein the self-cleaving peptide coding sequence is located between the heterologous ORF and the endogenous ORF; and the endogenous ORF is E1B-55k and the heterologous ORF is 3' to E1B-55k; the endogenous ORF is a DNA polymerase and the heterologous ORF is 5' to the DNA polymerase; the endogenous ORF is a DNA binding protein (DBP) and the heterologous ORF is 3' to the DBP; the endogenous ORF is an adenovirus death protein (ADP) and the heterologous ORF is 5' to ADP; the endogenous ORF is E3-14.7k and the heterologous ORF is 3' to E3-14.7k; the endogenous ORF is E4-ORF2 and the heterologous ORF is 5' to E4-ORF2; or the endogenous ORF is fiber and the heterologous ORF is 3' to the fiber; A recombinant adenoviral genome, wherein the heterologous ORF encodes a therapeutic protein. (Item 2) 2. The recombinant adenoviral genome of item 1, wherein the therapeutic protein comprises an immunomodulatory factor. (Item 3) 3. The recombinant adenovirus genome of claim 1 or 2, wherein the self-cleaving peptide is a 2A peptide or a variant thereof. (Item 4) 4. The recombinant adenovirus genome of item 3, wherein the 2A peptide comprises a porcine teschovirus-1 (PTV1) 2A (P2A) peptide, a foot-and-mouth disease virus (FMDV) 2A (F2A) peptide, an equine rhinitis A virus (ERAV) 2A (E2A) peptide, or a Thosea asigna virus (TaV) 2A (T2A) peptide, or a variant thereof. (Item 5) 5. The recombinant adenovirus genome according to item 4, wherein the amino acid sequence of the self-cleaving peptide is at least 80%, at least 85%, at least 90%, or at least 95% identical to any one of the amino acid sequences of SEQ ID NOs: 14 to 21. (Item 6) 5. The recombinant adenovirus genome according to item 4, wherein the self-cleaving peptide comprises any one of the amino acid sequences of SEQ ID NOs: 14 to 21. (Item 7) A composition comprising the recombinant adenovirus genome of any one of items 1 to 6 and a pharma- ceutically acceptable carrier. (Item 8) A recombinant adenovirus comprising the recombinant adenovirus genome of any one of items 1 to 6. (Item 9) A composition comprising the recombinant adenovirus according to item 8 and a pharma- ceutically acceptable carrier. A method for delivering a therapeutic protein to a subject, comprising administering to the subject a recombinant adenoviral genome described in any one of items 1 to 6, a recombinant adenovirus described in item 8, or a composition described in item 7 or item 9. (Item 11) A method for inhibiting tumor cell viability and / or tumor cell proliferation, comprising contacting the tumor cells with a recombinant adenovirus genome described in any one of items 1 to 6, a recombinant adenovirus described in item 8, or a composition described in item 7 or item 9. (Item 12) 12. The method according to item 11, which is an in vitro method. (Item 13) The method of claim 11, wherein the method is an in vivo method and contacting the tumor cells comprises administering the recombinant adenoviral genome, recombinant adenovirus, or composition to a subject having a tumor. (Item 14) A method for inhibiting tumor progression or reducing tumor volume in a subject, comprising administering to the subject a therapeutically effective amount of a recombinant adenovirus genome described in any one of items 1 to 6, a recombinant adenovirus described in item 8, or a composition described in item 7 or item 9, thereby inhibiting tumor progression or reducing tumor volume in the subject. (Item 15) A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a recombinant adenovirus genome described in any one of items 1 to 6, a recombinant adenovirus described in item 8, or a composition described in item 7 or item 9, thereby treating the cancer in the subject. (Item 16) 16. The method of any one of items 13 to 15, further comprising administering to the subject an additional therapeutic agent. (Item 17) (i) a recombinant adenovirus genome according to any one of items 1 to 6, a recombinant adenovirus according to item 8, or a composition according to item 7 or item 9; (ii) A kit comprising one or more additional therapeutic agents and / or one or more diagnostic agents. (Item 18) 18. The kit of item 17, wherein the one or more additional therapeutic agents comprises a chemotherapeutic agent, a biologic, or a combination thereof. (Item 19) 19. The kit according to item 17 or 18, wherein the one or more diagnostic agents comprise one or more antibodies specific for a tumor marker. (Item 20) 19. The kit according to item 17 or 18, wherein the one or more diagnostic agents comprise one or more nucleic acid molecules specific for a tumor marker. [Brief description of the drawings]
[0010] [Figure 1] Figure 1 is a schematic diagram of an exemplary workflow for testing adenovirus constructs. Whole viral genome plasmids are produced and transfected into suitable cells, e.g., 293-E4 cells, in multi-well plates. Once the transfected cells have expanded, they are subjected to freeze / thaw to release viral particles, followed by centrifugation to pellet cell debris. The supernatant (containing viral particles) is transferred to multiple larger culture plates. Viral particles are harvested from the transfected cells, CsCl purified, and infectious viral titers are measured by ELISA. The cell type of interest is then infected with the purified virus at a known MOI. 48 hours or 72 hours after infection, adenovirus late proteins, adenovirus genomes, or plaques are measured by Western blot, q-PCR, or plaque assay, respectively.
[0011] [Diagram 2]Figure 2 is a schematic diagram showing exponential virus growth. Exponential virus growth is necessary for oncolytic killing of all cells in a tumor. However, in most cases, only a small percentage of tumor cells are infected the first time. Thus, small differences in the number of progeny per replication result in large differences in the total number of particles after only a few replications. A comparison is shown between a virus that produces 3 virions per cycle and a virus that produces 5 virions per cycle. As shown in the graph, after 5-6 replications, the viral titers of these two viruses are significantly different.
[0012] [Diagram 3] Figure 3 is a schematic diagram showing an exemplary workflow of the fluorescence-based viral kinetics (FBVK) assay. A whole viral genome plasmid is produced (e.g., by Adsembly or AdSLIC) and used to transfect the cell type of interest in a multi-well plate. Alternatively, the cells are infected with recombinant adenoviral particles. The adenoviral genome contains at least one open reading frame (ORF) that encodes a fluorescent protein at a position in the viral genome that does not substantially change the viral replication kinetics. Fluorescence is monitored over time to calculate the viral replication kinetics. Candidate oncolytic viruses are those that exhibit the greatest difference in viral kinetics between tumor cells and normal cells.
[0013] [Figure 4A]Figures 4A-4B outline the kinetic assay environment when starting with adenoviral genomic plasmids. The assay does not require precise knowledge of initial transfection efficiency. Transfection conditions are chosen such that approximately 5-10% of cells are transfected the first time. In the example shown, a 48-well plate is used, which allows for testing 14 different viral constructs in triplicate, along with three mock-infected wells and three wells with FLUORESBRITE™ beads to compensate for tool sensitivity variations. (Figure 4A) The wells in the top half of the 48-well plate contain cells transfected with genomic plasmids of six different viruses, mock-infected cells, and blanks (FLUORESBRITE™ beads), each in triplicate. (Figure 4B) The wells in the bottom half of the 48-well plate contain cells transfected with genomic plasmids of eight different viruses, in triplicate. The multi-well plate is placed in a plate reader (such as a TECAN plate reader) for continuous fluorescence monitoring. [Figure 4B]Figures 4A-4B outline the kinetic assay environment when starting with adenoviral genomic plasmids. The assay does not require precise knowledge of initial transfection efficiency. Transfection conditions are chosen such that approximately 5-10% of cells are transfected the first time. In the example shown, a 48-well plate is used, which allows for testing 14 different viral constructs in triplicate, along with three mock-infected wells and three wells with FLUORESBRITE™ beads to compensate for tool sensitivity variations. (Figure 4A) The wells in the top half of the 48-well plate contain cells transfected with genomic plasmids of six different viruses, mock-infected cells, and blanks (FLUORESBRITE™ beads), each in triplicate. (Figure 4B) The wells in the bottom half of the 48-well plate contain cells transfected with genomic plasmids of eight different viruses, in triplicate. The multi-well plate is placed in a plate reader (such as a TECAN plate reader) for continuous fluorescence monitoring.
[0014] [Diagram 5] Figure 5 outlines the kinetic assay environment when starting with recombinant viruses. This assay does not require precise knowledge of the virus titer. The recombinant viruses are serially diluted and used to infect cells seeded in multi-well plates. In the example shown, a 96-well plate is used, and each virus is diluted 1:100, 1:300, 1:900, 1:2700, 1:8100, 1:24,300, 1:72,900, and 1:218,700, allowing 11 viruses to be tested simultaneously. Four wells are mock infected, and FLUORESBRITE™ beads are placed in four wells to compensate for tool sensitivity and variability. The multi-well plate is placed in a plate reader (such as a TECAN plate reader) for continuous fluorescence monitoring.
[0015] [Figure 6A]Figures 6A-6C show schematics of the Adsembly and AdSLIC techniques for the combinatorial assembly of recombinant adenoviruses. (Figure 6A) The adenovirus genome is divided into four modules - E1, Core, E3, and E4. (Figure 6B) Adsembly involves reassembly of the genome using a multisite Gateway reaction. (Figure 6C) AdSLIC utilizes sequence- and ligation-independent cloning (SLIC) to assemble adenovirus modules. [Figure 6B] Figures 6A-6C show schematics of the Adsembly and AdSLIC techniques for the combinatorial assembly of recombinant adenoviruses. (Figure 6A) The adenovirus genome is divided into four modules - E1, Core, E3, and E4. (Figure 6B) Adsembly involves reassembly of the genome using a multisite Gateway reaction. (Figure 6C) AdSLIC utilizes sequence- and ligation-independent cloning (SLIC) to assemble adenovirus modules. [Figure 6C] Figures 6A-6C show schematics of the Adsembly and AdSLIC techniques for the combinatorial assembly of recombinant adenoviruses. (Figure 6A) The adenovirus genome is divided into four modules - E1, Core, E3, and E4. (Figure 6B) Adsembly involves reassembly of the genome using a multisite Gateway reaction. (Figure 6C) AdSLIC utilizes sequence- and ligation-independent cloning (SLIC) to assemble adenovirus modules.
[0016] [Figure 7] 7 is a bar graph showing the natural logarithmic slope (ln-slope) of recombinant adenoviruses encoding fluorescent proteins in the E1 region. The values are shown for the construct YPet-E1A by direct fusion, as well as the YPet-P2A-E1A, E1A-P2A-mCherry, and E1B-55k-P2A-YPet constructs that contain P2A sites, respectively. The YPet-P2A-ADP construct is shown for comparison.
[0017] [Figure 8] FIG. 8 is a schematic representation of the analysis and interpretation of kinetic data from a fluorescence-based viral kinetics assay.
[0018] [Figure 9A] 9A-9C are bar graphs showing the natural log slope values of recombinant adenoviruses derived from Ad5, Ad9, or Ad34 and containing a heterologous ORF 3' of the E3-14.7k (or its equivalent in Ad9 and Ad34) ORF. Values are shown for Ad5 (E3-14.7k-P2A-YPet, PCMN-887), Ad9 (E3-15k-P2A-YPet, PCMN-888), and Ad34 (E3-14.8k-P2A-YPet, PCMN-889) in 293 cells (FIG. 9A), A549 cells (FIG. 9B), and U2OS cells (FIG. 9C). Values for chimeric viruses containing an Ad5 core (containing E3-14.7k-P2A-YPet) and a fiber shaft / knob derived from either Ad9 (Ad5 / Ad9) or Ad34 (Ad5 / Ad34) are also shown in each figure. [Figure 9B] 9A-9C are bar graphs showing the natural log slope values of recombinant adenoviruses derived from Ad5, Ad9, or Ad34 and containing a heterologous ORF 3' of the E3-14.7k (or its equivalent in Ad9 and Ad34) ORF. Values are shown for Ad5 (E3-14.7k-P2A-YPet, PCMN-887), Ad9 (E3-15k-P2A-YPet, PCMN-888), and Ad34 (E3-14.8k-P2A-YPet, PCMN-889) in 293 cells (FIG. 9A), A549 cells (FIG. 9B), and U2OS cells (FIG. 9C). Values for chimeric viruses containing an Ad5 core (containing E3-14.7k-P2A-YPet) and a fiber shaft / knob derived from either Ad9 (Ad5 / Ad9) or Ad34 (Ad5 / Ad34) are also shown in each figure. [Figure 9C]9A-9C are bar graphs showing the natural log slope values of recombinant adenoviruses derived from Ad5, Ad9, or Ad34 and containing a heterologous ORF 3' of the E3-14.7k (or its equivalent in Ad9 and Ad34) ORF. Values are shown for Ad5 (E3-14.7k-P2A-YPet, PCMN-887), Ad9 (E3-15k-P2A-YPet, PCMN-888), and Ad34 (E3-14.8k-P2A-YPet, PCMN-889) in 293 cells (FIG. 9A), A549 cells (FIG. 9B), and U2OS cells (FIG. 9C). Values for chimeric viruses containing an Ad5 core (containing E3-14.7k-P2A-YPet) and a fiber shaft / knob derived from either Ad9 (Ad5 / Ad9) or Ad34 (Ad5 / Ad34) are also shown in each figure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] (Sequence Listing) The nucleic acid and amino acid sequences listed in the attached sequence listing are shown using standard abbreviations for nucleotide bases and three-letter codes for amino acids as defined in 37 CFR 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included by any reference to the strand shown. The sequence listing has been submitted as a 703KB ASCII text file created on February 21, 2017, and is incorporated herein by reference. In the attached sequence listing: SEQ ID NO:1 is the nucleotide sequence of the synthetic adenoviral genome CMBT-379 (YPet-P2A-E1A). SEQ ID NO:2 is the nucleotide sequence of the synthetic adenoviral genome CMBT-432 (E1A-P2A-YPet). SEQ ID NO:3 is the nucleotide sequence of the synthetic adenoviral genome CMBT-456 (E1B-55k-P2A-YPet). SEQ ID NO:4 is the nucleotide sequence of the synthetic adenoviral genome CMBT-499 (E1B-55k-P2A-mCherry). SEQ ID NO:5 is the nucleotide sequence of the synthetic adenoviral genome CMBT-530 (YPet-P2A-(DNA poly)). SEQ ID NO:6 is the nucleotide sequence of the synthetic adenoviral genome CMBT-886 (DBP-P2A-YPet). SEQ ID NO:7 is the nucleotide sequence of the synthetic adenoviral genome CMBT-403 (YPet-P2A-ADP). SEQ ID NO:8 is the nucleotide sequence of the synthetic adenoviral genome CMBT-429 (ADP-P2A-YPet). SEQ ID NO:9 is the nucleotide sequence of the synthetic adenoviral genome PCMN-887 (E3-14.7k-P2A-YPet). SEQ ID NO:10 is the nucleotide sequence of the synthetic adenoviral genome CMBT-457 (YPet-P2A-E4-ORF2). SEQ ID NO:11 is the nucleotide sequence of the synthetic adenoviral genome CMBT-633 (mCherry-P2A-E4-ORF2). SEQ ID NO:12 is the nucleotide sequence of the synthetic adenoviral genome CMBT-407 (YPet-P2A-fiber). SEQ ID NO:13 is the nucleotide sequence of the synthetic adenoviral genome CMBT-445 (Fiber-P2A-YPet). SEQ ID NO:14 is the amino acid sequence of P2A. SEQ ID NO:15 is the amino acid sequence of F2A. SEQ ID NO: 16 is the amino acid sequence of E2A. SEQ ID NO:17 is the amino acid sequence of T2A. SEQ ID NO:18 is the amino acid sequence of a modified P2A containing GSG at the N-terminus. SEQ ID NO:19 is the amino acid sequence of a modified F2A containing GSG at the N-terminus. SEQ ID NO:20 is the amino acid sequence of a modified E2A containing GSG at the N-terminus. SEQ ID NO:21 is the amino acid sequence of a modified T2A containing GSG at the N-terminus. SEQ ID NO:22 is the nucleotide sequence of the synthetic adenoviral genome PCMN-888 (Ad9 E3-15k-P2A-YPet). SEQ ID NO:23 is the nucleotide sequence of the synthetic adenoviral genome PCMN-889 (Ad34 E3-14.8k-P2A-YPet).
[0020] I. Abbreviations Ad Adenovirus ADP Adenovirus death protein BFP Blue fluorescent protein E2A Equine rhinitis A virus 2A ELISA enzyme-linked immunosorbent assay ERAV Equine rhinitis A virus F2A Foot and mouth disease virus 2A FACS Fluorescence Activated Cell Sorting FMDV Foot and mouth disease virus GFP Green Fluorescent Protein MOI Multiplicity of infection OD optical density ORF Open Reading Frame P2A Porcine teschovirus-1 2A pIX Protein IX PTV1 Porcine teschovirus-1 RFP Red fluorescent protein SLIC Sequence- and Ligation-Independent Cloning T2A Thosea asigna virus 2A TaV Thosea asigna virus YFP Yellow Fluorescent Protein
[0021] II. Terms and Methods Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology can be found in Benjamin Lewin, Genes V (ISBN 0-19-854287-9), published by Oxford University Press in 1994; Kendrew et al. (eds.), The Encyclopedia of Molecular Biology (ISBN 0-632-02182-9), published by Blackwell Science Ltd. in 1994; and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference (ISBN 1-56081-569-8), published by VCH Publishers, Inc. in 1995.
[0022] In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided.
[0023] 2A peptide: a type of self-cleaving peptide encoded by some RNA viruses, such as picornaviruses. 2A peptides function by causing the ribosome to skip synthesis of a peptide bond at the C-terminus of the 2A element, resulting in separation of the end of the 2A sequence from the downstream peptide (Kim et al., PLoS One, Vol. 6(4), e18556, 2011). "Cleavage" occurs between the glycine and proline residues found at the C-terminus of the 2A peptide. Exemplary 2A peptides include, but are not limited to, 2A peptides encoded by Thosea asigna virus (TaV), Equine rhinitis A virus (ERAV), Porcine teschovirus-1 (PTV1), and Foot and Mouth Disease virus (FMDV), which are described herein as SEQ ID NOs: 14-17. In some embodiments, the 2A peptide contains Gly-Ser-Gly at the N-terminus to improve cleavage efficiency (SEQ ID NOs: 18-21).
[0024] Adenovirus: a non-enveloped virus with a linear double-stranded DNA genome and an icosahedral capsid. Currently, 68 serotypes of human adenovirus are known, classified into seven species (species A, B, C, D, E, F, and G). Different serotypes of adenovirus are associated with different types of disease, with some serotypes causing respiratory disease (mainly species B and C), conjunctivitis (species B and D), and / or gastroenteritis (species F and G).
[0025] Adenovirus death protein (ADP): A protein synthesized late during adenovirus infection that mediates cell lysis and release of adenovirus to infect other cells. ADP is a 101 amino acid integral membrane glycoprotein that localizes to the nuclear envelope, endoplasmic reticulum, and Golgi apparatus. ADP was previously designated E3-11.6K).
[0026] Administration: Providing or giving to a subject an agent, such as a therapeutic agent (e.g., a recombinant virus), by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, intratumoral, and intravenous), oral, intraductal, sublingual, rectal, transdermal, intranasal, vaginal, and inhalation routes.
[0027] Chimeric: composed of at least two parts of different origin. In the context of this disclosure, a "chimeric adenovirus" is an adenovirus having genetic material and / or proteins from at least two different serotypes (e.g., from Ad5 and a second serotype of adenovirus). In this context, a "capsid-swapped" adenovirus refers to a chimeric adenovirus in which the capsid proteins are from one serotype of adenovirus and the remaining proteins are from another adenovirus serotype. Similarly, a "chimeric fiber" is a fiber protein having amino acid sequences from at least two different serotypes of adenovirus. For example, a chimeric fiber can be composed of a fiber shaft from Ad5 and a fiber knob from a second serotype of adenovirus. In another example, a chimeric fiber is composed of an Ad5 tail and a fiber shaft and knob from a second serotype of adenovirus (such as Ad9 or Ad34).
[0028] Contacting: To bring into direct physical association and includes both solid and liquid forms.
[0029] Degenerate variant: In the context of this disclosure, a "degenerate variant" refers to a polynucleotide encoding a peptide that contains a sequence that is degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Thus, all degenerate nucleotide sequences that encode a peptide are included, as long as the amino acid sequence of the peptide encoded by the nucleotide sequence is unchanged.
[0030] Deleted: An adenovirus genome encoding a "deleted" protein (such as an E4orf1 or E4orf6 / 7 protein) refers to an adenovirus having a complete deletion of the protein coding sequence or a partial deletion that results in the absence of protein expression.
[0031] E2F deregulation: refers to increased activity of E2F transcription factors and downstream target genes, which occurs in almost all types of human cancer. Deregulation of E2F pathway activity and transcription can result from a variety of different mutations in any upstream components of the pathway, such as loss-of-function mutations and deletions of Rb, p107, and p130 tumor suppressors. Rb was the first tumor suppressor identified and is absent or mutated in at least one-third of human tumors. In addition, p16 mutations and / or epigenetic silencing can activate E2F in tumor cells. Mutations, gene amplification, or overexpression of cyclin D and CDK4 can also result in deregulation of E2F activity in human tumors. In addition, E2F is activated by mutations in growth factor receptor pathways, including EGFR, RTK, RAS, RAF, PI-3K, PTEN, RAF, MYC. p16 INK4a -Mutations in the cyclin D: cdk4 / 6-RB-E2F pathway generally occur in a mutually exclusive manner, so that one "hit" (e.g., p16) does not come with the other (e.g., Rb mutation or cyclin D: cdk overexpression). However, most current chemotherapeutics inhibit the transcriptional targets of E2F, but are also toxic to normal cells and are proliferative poisons that often have devastating iatrogenic complications. As disclosed herein, an alternative therapeutic approach is to use a virus that selectively undergoes lytic replication in cancer cell lesions that have deregulation of the p16-cyclin D: cdk4-RB-E2F pathway.
[0032] DNA-binding protein (DBP): This adenoviral protein binds to single-stranded DNA and RNA, as well as double-stranded DNA. DBP, a 72 kilodalton protein, is essential for adenoviral DNA replication.
[0033] E1A: adenovirus early region 1A (E1A) gene and the polypeptide expressed from this gene. E1A protein plays a role in viral genome replication by making cells enter the cell cycle. As used herein, the term "E1A protein" refers to the protein expressed from the E1A gene, and includes the E1A protein produced by any adenovirus serotype.
[0034] E3-RIDα / RIDβ and E3-14.7k: Early expression proteins produced by the E3 gene. E3-RIDα, E3-RIDβ, and E3-14.7k proteins form the receptor internalization and degradation complex (RID), which causes the endocytosis and degradation of various receptors, including CD95 (FasL receptor) and TNFR1 and 2 (TNF / TRAIL receptors), to localize to the nuclear membrane and protect infected cells from the host's antiviral response. The coding sequences of E3-RIDα, E3-RIDβ, and E3-14.7k are adjacent to each other in this order.
[0035] E4orf1: an adenoviral protein produced by the E4 gene. The term "E4orf1 protein" includes the E4orf1 protein produced by the E4 gene from any adenovirus serotype.
[0036] E4orf6 / 7: A protein encoded by the adenovirus E4 gene. The term "E4orf6 / 7 protein" includes the E4orf6 / 7 protein produced by the E4 gene from any adenovirus serotype.
[0037] Fiber: The adenovirus fiber protein is a trimeric protein that mediates binding to cell surface receptors. The fiber protein consists of a long N-terminal shaft and a globular C-terminal knob.
[0038] Fluorescent protein: A protein that emits light of a specific wavelength when exposed to light of a specific wavelength. Fluorescent proteins include green fluorescent protein (such as GFP, EGFP, AcGFP1, Emerald, Superfolder GFP, Azami Green, mWasabi, TagGFP, TurboGFP, and ZsGreen), blue fluorescent protein (such as EBFP, EBFP2, Sapphire, T-Sapphire, Azurite, and mTagBFP), cyan fluorescent protein (such as ECFP, mECFP, Cerulean, CyPet, AmCyan1, Midori-Ishi Cyan, mTurquoise, and mTFP1), yellow fluorescent protein (EYFP, Topaz, Venus, mCitrine, YPet, TagYFP, PhiYFP, ZsYellow1, and mBanana), orange fluorescent protein (Kusabira Orange, Kusabira Orange2, mOrange, mOrange2, and mTangerine), red fluorescent proteins (mRuby, mApple, mStrawberry, AsRed2, mRFP1, JRed, mCherry, HcRed1, mRaspberry, dKeima-Tandem, HcRed-Tandem, mPlum, AQ143, tdTomato, and E2-Crimson), orange / red fluorescent proteins (dTomato, dTomato-Tandem, TagRFP, TagRFP-T, DsRed, DsRed2, DsRed-Express(T1), and DsRed-Monomer), and modified versions thereof.
[0039] Fusion protein: a protein that contains amino acid sequences derived from at least two different (heterologous) proteins or peptides. Fusion proteins can be produced, for example, by expression of a nucleic acid sequence engineered from nucleic acid sequences that code for at least a portion of two different (heterologous) proteins. To create a fusion protein, the nucleic acid sequences must be in the same reading frame and must not contain internal stop codons. Fusion proteins, especially short fusion proteins, can also be produced by chemical synthesis.
[0040] Heterologous: Heterologous protein or polypeptide refers to a protein or polypeptide derived from a different source or species.
[0041] Hexon: The major adenovirus capsid protein.
[0042] Immunomodulator: An agent that alters (e.g., activates, enhances, or suppresses) the immune system. Immunomodulators include, but are not limited to, cytokines (such as interleukin 2 (IL-2), IL-7, IL-12, GM-CSF, FLT3 ligand, or interferon), chemokines (such as CCL3, CCL26, CXCL7, CXCL9, and CXCL10), T cell activation ligands (such as anti-CD3 antibodies or alloantigens), costimulatory molecules (such as B7.1 / B7.2, OX40L, 4-1-BBL, or CD40L), checkpoint blockade inhibitors (such as anti-PD-1 antibodies or anti-CTLA4 antibodies), and small molecule immunomodulators.
[0043] Isolated: An "isolated" biological component (such as a nucleic acid molecule, protein, virus, or cell) has been substantially separated or purified from other biological components, such as other chromosomal and extrachromosomal DNA and RNA, proteins, and cells in the cells or tissues of an organism or the organism itself in which it naturally occurs. "Isolated" nucleic acid molecules and proteins include those purified by standard purification methods. The term also encompasses nucleic acid molecules and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acid molecules and proteins.
[0044] Modification: A change in the sequence of a nucleic acid or a protein sequence. For example, modifications of an amino acid sequence include, for example, substitution, insertion, and deletion, or a combination thereof. Insertions include amino-terminal and / or carboxyl-terminal fusions, and insertions of single or multiple amino acid residues into a sequence. Deletions are characterized by the removal of one or more amino acid residues from a protein sequence. In some embodiments herein, modifications (such as substitutions, insertions, or deletions) result in a change in function, such as a reduction or enhancement of a specific activity of a protein. As used herein, "Δ" or "delta" refers to a deletion. Substitution modifications are those in which at least one residue is removed and a different residue is inserted in its place. Amino acid substitutions are typically of a single residue, but may occur simultaneously at several different positions. Substitutions, deletions, insertions, or any combination thereof may be combined to arrive at a final mutant sequence. These modifications can be prepared by modification of nucleotides in the DNA encoding the protein, thereby producing a DNA encoding this modification. Techniques for making insertion, deletion, and substitution mutations at predetermined sites in DNA having a known sequence are well known in the art. A "modified" protein, nucleic acid, or virus is one that has one or more of the modifications outlined above.
[0045] Neoplasia, Malignancy, Cancer, and Tumor: A neoplasia is an abnormal growth of tissue or cells resulting from excessive cell division. Neoplastic growth can produce a tumor. The amount of tumor in an individual is the "tumor burden" and can be measured as the number, volume, or weight of tumors. Tumors that do not metastasize are referred to as "benign." Tumors that can invade surrounding tissues and / or metastasize are referred to as "malignant." Malignant tumors are also referred to as "cancer."
[0046] Hematological cancer is cancer of blood or bone marrow. Examples of hematological (or hematopoietic) cancer include leukemia, such as acute leukemia (such as acute lymphocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia, and myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia), chronic leukemia (such as chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and aggressive forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia, and myelodysplasia. In some cases, lymphoma is considered as a solid tumor.
[0047] A solid tumor is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named according to the type of cells that form them (such as sarcoma, carcinoma, and lymphoma). Examples of solid tumors, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovial tumors, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, lymphoid malignancies, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytoma, sebaceous gland carcinoma, papillary carcinoma, human papillomavirus (HPV)-infected neoplasia, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, cholangiocarcinoma, choriocarcinoma, Wilms' tumor, cervical carcinoma, cancer), testicular tumors, seminoma, bladder cancer, melanoma, and CNS tumors, such as gliomas (such as brain stem gliomas and mixed gliomas), glioblastomas (also known as glioblastoma multiforme), astrocytomas, CNS lymphomas, germinomas, medulloblastomas, schwannomas, craniopharyogiomas, ependymomas, pinealomas, hemangioblastomas, acoustic neuromas, oligodendroglioma, meningiomas, neuroblastomas, retinoblastomas, and brain metastases.
[0048] Oncolytic virus: It is a virus that selectively kills the cell of proliferation disorder, such as cancer / tumor cell.The killing of cancer cell can be detected by any method established in the art, such as by determining the number of viable cells, or by detecting the cytopathic effect, apoptosis, or synthesis of viral protein in cancer cell (for example, by metabolic labeling of viral gene required for replication, immunoblot, or RT-PCR), or the reduction in tumor size.
[0049] Operably linked: A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence when it affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.
[0050] Pharmaceutically acceptable carriers: Pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 15th Edition (1975), by E. W. Martin, describes the use of one or more therapeutic compounds in a pharmaceutical composition. Compositions and formulations suitable for pharmaceutical delivery of objects, molecules, or agents (eg, the recombinant viruses disclosed herein) are described.
[0051] Generally, the nature of the carrier will depend on the specific mode of administration used.For example, parenteral formulations usually contain injectable fluids, which contain pharma- ceutically and physiologically acceptable fluids, such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol, etc., as vehicles.For solid compositions (e.g., in the form of powder, pill, tablet, or capsule), conventional non-toxic solid carriers can include, for example, pharmaceutical grade mannitol, lactose, starch, or magnesium stearate.In addition to biologically neutral carriers, pharmaceutical compositions to be administered may contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents, for example, sodium acetate or sorbitan monolaurate.
[0052] Polypeptide, peptide, or protein: A polymer in which the monomers are amino acid residues that are joined together through amide bonds. When the amino acids are alpha amino acids, either the L-optical isomer or the D-optical isomer can be used. The terms "polypeptide", "peptide", and "protein" are used interchangeably herein. These terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acids, as well as to naturally occurring and non-naturally occurring amino acid polymers. The term "residue" or "amino acid residue" includes reference to an amino acid that is incorporated into a protein, polypeptide, or peptide.
[0053] A conservative substitution in a polypeptide is the substitution of one amino acid residue in a protein sequence for a different amino acid residue that has similar biological properties. Typically, a conservative substitution has little or no effect on the activity of the resulting polypeptide. For example, a protein or peptide that contains one or more conservative substitutions (e.g., not more than one, not more than two, not more than three, not more than four, or not more than five substitutions) retains the structure and function of the wild-type protein or peptide. A polypeptide can be produced to contain one or more conservative substitutions by manipulating the nucleotide sequence that encodes the polypeptide, for example, using standard procedures such as site-directed mutagenesis or PCR. In one example, such variants can be easily selected by testing the cross-reactivity of antibodies or the ability of the antibodies to induce an immune response. Examples of conservative substitutions are shown below. [Table 1]
[0054] Conservative substitutions generally maintain (a) the structure of the polypeptide backbone, e.g., as a sheet or helix conformation, in the area of the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
[0055] In general, the substitutions predicted to result in the greatest changes to protein properties will be non-conservative, e.g., (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or is substituted by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; (b) a cysteine or proline is substituted for (or is substituted by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or is substituted by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or is substituted by) one having no side chain, e.g., glycine.
[0056] Preventing, Treating, or Ameliorating a Disease: "Preventing" a disease refers to inhibiting the full development of a disease. "Treating" refers to a therapeutic intervention that alleviates the signs or symptoms of a disease or condition after its development has begun. "Ameliorating" refers to a reduction in the number or severity of signs or symptoms of a disease.
[0057] Promoter: A region of DNA that directs / initiats the transcription of a nucleic acid (e.g., a gene). A promoter contains the necessary nucleic acid sequences near the start site of transcription. Typically, a promoter is located near the gene to be transcribed. A promoter also optionally contains distal enhancer or repressor elements, which may be located as far away as several thousand base pairs from the transcription start site. A "constitutive promoter" is a promoter that is continuously active and is not subject to control by external signals or molecules. In contrast, the activity of an "inducible promoter" is controlled by external signals or molecules (e.g., transcription factors or tetracycline).
[0058] Protein IX (pIX): A minor component of the adenovirus capsid that associates with the hexon protein.
[0059] Purified: The term "purified" is intended as a relative term, without requiring absolute purity. Thus, for example, a purified peptide, protein, virus, or other active compound is one that has been isolated, in whole or in part, from naturally associated proteins and other contaminants. In certain embodiments, the term "substantially purified" refers to a peptide, protein, virus, or other active compound that has been isolated from cells, cell culture medium, or other crude preparations and has been subjected to fractionation to remove various components of the initial preparation, e.g., proteins, cell debris, and other components.
[0060] Recombinant: A recombinant nucleic acid molecule, protein, or virus is one that has a sequence that does not occur in nature or that is created by the artificial combination of two segments of otherwise distinct sequences. This artificial combination can be accomplished by chemical synthesis or by the artificial manipulation of segments of isolated nucleic acid molecules, e.g., by genetic engineering techniques. The term "recombinant" also includes nucleic acids, proteins, and viruses that have been altered only by the addition, substitution, or deletion of portions of the naturally occurring nucleic acid molecule, protein, or virus.
[0061] Replication deficiency: Adenovirus that exhibits "replication deficiency" in non-tumor cells (compared to tumor cells) refers to adenovirus that exhibits reduced viral replication in normal cells compared to tumor cells.Replication deficiency is manifested, for example, by the lack of viral late protein expression in normal cells, reduced viral DNA synthesis, reduced ability to induce E2F target genes (e.g., cyclin A and B), reduced ability to induce S phase entry, and / or reduced ability to induce cell killing compared to tumor cells.
[0062] Replication-deficient virus: A virus that preferentially inhibits cell proliferation, causes cell lysis, or induces apoptosis (collectively considered as killing) in a given cell population with a given phenotype (e.g., tumor cells with deregulation of the E2F pathway). Such viruses are unable or have limited ability to reduce or inhibit cell proliferation, cause cell lysis, induce apoptosis, or replicate in cells that do not otherwise have the given cell phenotype (such as normal non-tumor cells).
[0063] Self-cleaving peptide: It is a peptide that induces ribosome to skip the synthesis of peptide bond at C-terminus, resulting in separation of the peptide sequence from downstream polypeptide. Virus-encoded 2A peptide is a kind of self-cleaving peptide. Virus-encoded 2A peptide includes, for example, porcine teschovirus-1 (PTV1), foot and mouth disease virus (FMDV), equine rhinitis A virus (ERAV), and Thosea asigna virus (TaV) derived 2A peptide.
[0064] Sequence identity: The identity or similarity between two or more nucleic acid sequences or between two or more amino acid sequences is expressed as the identity or similarity between the sequences. Sequence identity can be measured as a percentage of identity, the higher the percentage, the more identical the sequences. Sequence similarity can be measured as a percentage of similarity (taking into account conservative amino acid substitutions), the higher the percentage, the more similar the sequences. Homologs or orthologs of nucleic acid or amino acid sequences have a relatively high degree of sequence identity / similarity when aligned using standard methods. This homology is more pronounced when orthologous proteins or cDNAs are from more closely related species (e.g., human and mouse sequences) compared to more distantly related species (e.g., human and C.Elegans sequences).
[0065] Methods for aligning sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math., vol. 2, p. 482, 1981; Needleman and Wunsch, J. Mol. Biol., vol. 48, p. 443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85, 2444, 1988; Higgins and Sharp, Gene, 73, 237-44, 1988; Higgins and Sharp, CABIOS, 5, 151-3, 1989; Corpet et al., Nuc. Acids Res., 16, 10881-90, 1988; Huang et al., Computer Appls. in the Biosciences, 8, 155-65, 1992; and Pearson et al., Meth. Mol. Bio., 24, 307-31, 1994. Altschul et al., J. Mol. Biol., 215, 403-10, 1990, present a detailed discussion of sequence alignment methods and homology calculations.
[0066] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol., vol. 215, pp. 403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI) and the Internet, for use in conjunction with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx. Additional information can be found at the NCBI website.
[0067] Serotype: A group of closely related microorganisms (such as viruses) distinguished by a characteristic set of antigens.
[0068] Subject: Living multi-cellular vertebrate organisms, a category that includes human and non-human mammals.
[0069] Synthetic: Produced by artificial means in a laboratory, for example, a synthetic nucleic acid or protein can be chemically synthesized in a laboratory.
[0070] Therapeutic agent: Any agent capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject. Therapeutic agents include, but are not limited to, chemical compounds, small molecules, recombinant viruses, antisense compounds, antibodies (or antigen-binding fragments thereof), peptides, or nucleic acid molecules. For example, therapeutic agents for treating cancer include agents that prevent or inhibit tumor growth, tumor development, and tumor metastasis. A "therapeutic protein" is a therapeutic agent that is a protein or peptide, including an antibody or an antigen-binding fragment thereof. In some embodiments herein, the therapeutic protein is an immunomodulator. In other embodiments, the therapeutic protein is a toxin, Fas or FasL, a soluble deathfactor, a mediator of bystander destruction. , tumor antigens, neoantigens, or alloantigens.
[0071] Therapeutically effective amount: A quantity of a particular pharmaceutical or therapeutic agent (e.g., a recombinant virus) that is sufficient to achieve a desired effect in a subject or cell being treated with the agent. The effective amount of the agent may depend on several factors, including, but not limited to, the subject or cell being treated, as well as the mode of administration of the therapeutic composition.
[0072] U exon: An open reading frame located in the I strand (leftward transcription) between the early E3 region and the fiber gene (Tollefson et al., J Virol, vol. 81 (23), pp. 12918-12926).
[0073] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. The singular terms "a", "an" and "the" include plural references unless the context clearly indicates otherwise. "Comprising A or B" means including A, or B, or A and B. It should be further understood that all base or amino acid sizes and all molecular weight or molecular mass values given for nucleic acids or polypeptides are approximate and are provided for illustration purposes. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification will control, including explanations of terms. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
[0074] III. Overview of the embodiment The present specification discloses a recombinant adenovirus genome, which comprises a heterologous open reading frame (ORF) and a self-cleaving peptide coding sequence.The heterologous ORF can, for example, code for a therapeutic protein (e.g., an immunomodulator).The recombinant adenovirus genome and the recombinant adenovirus produced by the disclosed genome can be used in a variety of different therapeutic applications, such as, for example, the treatment of cancer.
[0075] Provided herein is a recombinant adenovirus genome that includes a heterologous ORF and a self-cleaving peptide coding sequence, both in the same reading frame as and operably linked to an endogenous adenovirus ORF, wherein the self-cleaving peptide coding sequence is located between the heterologous ORF and the endogenous ORF. In some embodiments, the endogenous ORF is E1B-55k and the heterologous ORF is 3' of E1B-55k; the endogenous ORF is DNA polymerase and the heterologous ORF is 5' of the DNA polymerase; the endogenous ORF is DNA binding protein (DBP) and the heterologous ORF is 3' of DBP; the endogenous ORF is adenovirus death protein (ADP) and the heterologous ORF is 5' of ADP; the endogenous ORF is E3-14.7k and the heterologous ORF is 3' of E3-14.7k; the endogenous ORF is E4-ORF2 and the heterologous ORF is 5' of E4-ORF2; or the endogenous ORF is fiber and the heterologous ORF is 3' of fiber.
[0076] In some embodiments, the heterologous ORF encodes a therapeutic protein.
[0077] In some embodiments, the self-cleaving peptide is a 2A peptide or a variant thereof. In some examples, the 2A peptide comprises a porcine teschovirus-1 (PTV1) 2A (P2A) peptide, a foot and mouth disease virus (FMDV) 2A (F2A) peptide, an equine rhinitis A virus (ERAV) 2A (E2A) peptide, or a Thosea asigna virus (TaV) 2A (T2A) peptide, or a variant thereof. In certain examples, the P2A peptide sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 18. In some examples, the 2A peptide variant comprises an additional amino acid sequence (such as GSG) at the N-terminus.
[0078] In certain embodiments, the F2A peptide sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 19. In certain embodiments, the E2A peptide sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 16 or SEQ ID NO: 20. In certain embodiments, the T2A peptide sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 21. In certain non-limiting embodiments, the self-cleaving peptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 14-21.
[0079] In some embodiments, the adenovirus is adenovirus type 5 (Ad5). In other embodiments, the adenovirus is Ad2, Ad3, Ad9, Ad11, Ad12, or Ad34. In yet other embodiments, the adenovirus is a chimeric adenovirus, such as, but not limited to, an Ad5 / Ad9 or Ad5 / Ad34 chimeric adenovirus.
[0080] Further provided herein is a recombinant adenovirus comprising the recombinant adenovirus genome disclosed herein.
[0081] The recombinant adenovirus (and recombinant adenovirus genome) provided herein can optionally include additional modifications, for example, to target the virus to specific cell types, to inhibit targeting and replication in the liver, to allow selective replication in tumor cells, and to avoid pre-existing neutralizing antibodies against common adenovirus serotypes.Additional modifications can vary according to the desired use of the recombinant adenovirus.Adenovirus modifications are described, for example, in PCT Application No. PCT / US2015 / 051745 (filed on September 23, 2015), International Publication No. WO 2012 / 024350, International Publication No. WO 2013 / 138505, and International Publication No. WO 2014 / 153204, which are incorporated herein by reference in their entirety.
[0082] Also provided by the present disclosure are compositions comprising a recombinant adenoviral genome or a recombinant adenovirus and a pharma- ceutically acceptable carrier.
[0083] Also provided herein is a method for delivering therapeutic protein to a subject.In some embodiments, the method comprises administering to a subject recombinant adenovirus genome, recombinant adenovirus or composition disclosed herein.In these methods, the heterologous ORF of recombinant adenovirus or recombinant adenovirus genome codes for therapeutic protein.
[0084] Further provided are methods of reducing or inhibiting tumor cell viability and / or tumor cell proliferation (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 75%, at least 90%, at least 95%, or at least 98% reduction compared to the absence of the disclosed therapy). In some embodiments, the method comprises contacting a tumor cell with a recombinant adenoviral genome, recombinant adenovirus, or composition disclosed herein. In these methods, the heterologous ORF encodes a therapeutic protein. In some examples, the method is an in vitro method. In other examples, the method is an in vivo method, and contacting the tumor cell comprises administering a recombinant adenoviral genome, recombinant adenovirus, or composition to a subject having a tumor.
[0085] Further provided herein are methods of reducing or inhibiting tumor progression, such as by reducing the number and / or size of metastases or reducing tumor volume in a subject (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 75%, at least 90%, at least 95%, or at least 98% reduction, compared to the absence of the disclosed treatment). In some embodiments, the method comprises administering to a subject a therapeutically effective amount of a recombinant adenovirus genome, recombinant adenovirus, or composition disclosed herein. In these methods, the heterologous ORF encodes a therapeutic protein.
[0086] Further provided is a method for treating cancer in a subject.In some embodiments, the method comprises administering to the subject a therapeutically effective amount of the recombinant adenovirus genome, recombinant adenovirus or composition disclosed herein.In these methods, the heterologous ORF encodes a therapeutic protein.
[0087] In some embodiments herein, the method further comprises administering to the subject an additional therapeutic agent. For example, the additional therapeutic agent can include an anti-cancer agent, such as a chemotherapeutic agent, a biologic (such as an antibody or a fragment thereof, such as a monoclonal antibody), or a nucleic acid molecule, such as an inhibitory nucleic acid molecule, or other therapeutic treatment, such as tumor surgical removal or tumor irradiation.
[0088] Also provided herein is a kit, comprising the recombinant adenovirus genome, recombinant adenovirus, or composition disclosed herein and one or more additional therapeutic agents and / or one or more diagnostic agents.In some embodiments, the one or more additional therapeutic agents comprise chemotherapeutic agents, biologics, or combinations thereof.In some examples, the one or more diagnostic agents comprise one or more antibodies or nucleic acid molecules specific for tumor markers, or imaging probes that can be used to track viruses or tumor cells in vitro or in vivo.
[0089] IV. Optimal Placement of Exogenous ORFs The 36 kb adenovirus genome is small and uses both the top and bottom strands to code for various genes. At many locations in the adenovirus genome, both the top and bottom strands are used simultaneously to code for separate genes. The size of the genome has evolved to be optimal for insertion into its capsid. As a result, the insertion of exogenous genes is limited by the size capacity of the capsid, because the addition of excessive exogenous nucleic acid leads to incomplete genome loading into the capsid and reduced viral kinetics.
[0090] The solution to the problem presented by the limited space available in the adenovirus genome is to position an exogenous open reading frame (ORF) as a fusion product within the original adenovirus ORF. This strategy utilizes the adenovirus promoter, 5'UTR and polyA tail already encoded in the genome. However, the expression of the fusion of an original adenovirus protein with an exogenous protein may be detrimental to the function of one or both proteins, resulting in a significant decrease in adenovirus replication kinetics.
[0091] The present disclosure provides a solution to this problem by using a self-cleaving peptide sequence that is placed between native (endogenous) ORF and exogenous (heterologous) ORF.When placed between two ORFs on a single mRNA, the presence of the self-cleaving peptide sequence causes ribosome skipping, and the first protein is released separately from the second protein.In some embodiments disclosed herein, the self-cleaving peptide is 2A peptide (P2A).
[0092] Also disclosed herein is the identification of the optimal placement site of heterologous ORF in the adenovirus genome. The combination of self-cleaving peptide sequence and good placement of heterologous ORF results in high expression and minimal or no effect on virus dynamics.
[0093] As described in Example 1 below, multiple sites were identified in the adenovirus genome where the heterologous ORF was inserted without inhibiting adenovirus replication kinetics. Specifically, it was determined that the heterologous ORF could be inserted C-terminally to the E1B-55k ORF, N-terminally to the DNA polymerase ORF, C-terminally to the DBP ORF, N-terminally to the ADP ORF, C-terminally to the E3-14.7k ORF, or N-terminally to the E4-ORF2. In each case, a self-cleaving peptide sequence (P2A site) was inserted between the adenovirus ORF and the heterologous ORF. It is further disclosed herein that the insertion of the heterologous ORF C-terminally to the fiber produced a replication-deficient adenovirus, however, this recombinant virus was capable of producing extremely high levels of heterologous protein in infected cells, which may prove useful in some therapeutic applications.
[0094] Thus, the present disclosure contemplates the use of the following recombinant adenoviruses for therapeutic applications ("SC" refers to the sequence encoding a self-cleaving peptide, such as P2A): E1B-55k-SC-Heterogeneous ORF Heterologous ORF-SC-(DNA polymerase) DBP-SC-heterogeneous ORF Heterogeneous ORF-SC-ADP E3-14.7k-SC-Heterogeneous ORF Heterogeneous ORF-SC-E4-ORF2 Fiber-SC-Heterologous ORF
[0095] In some embodiments herein, the self-cleaving peptide is the virally encoded 2A peptide, or a modified version thereof as further described below.
[0096] V. Self-cleaving peptide sequences A self-cleaving peptide is a peptide that induces ribosomes to skip the synthesis of peptide bonds at the C-terminus, resulting in the separation of the peptide sequence from the downstream polypeptide. The use of self-cleaving peptides allows the expression of multiple proteins flanked by self-cleaving peptides from a single ORF. The 2A peptide encoded by viruses is one type of self-cleaving peptide.
[0097] Similar to other self-cleaving peptides, the 2A peptide functions by causing the ribosome to skip synthesis of the peptide bond at the C-terminus of the 2A element, resulting in separation of the end of the 2A sequence from the downstream peptide (Kim et al., PLoS One, vol. 6(4): e18556, 2011). The "cleavage" occurs between the glycine and proline residues found at the C-terminus of the 2A peptide. Exemplary 2A peptides include Thosea These include, but are not limited to, the 2A peptides encoded by TaV, Equine rhinitis A virus (ERAV), Porcine teschovirus-1 (PTV1), and Foot and Mouth Disease virus (FMDV), or modified versions thereof.
[0098] In certain examples herein, the 2A peptide includes PTV1 2A (P2A), FMDV 2A (F2A), ERAV 2A (E2A), or TaV 2A (T2A), the sequences of which are shown below and described herein as SEQ ID NOs: 14-17. [ka]
[0099] In some examples, the 2A peptide is modified to include Gly-Ser-Gly at the N-terminus to improve cleavage efficiency. The sequences of modified P2A, F2A, E2A, and T2A are shown below and described herein as SEQ ID NOs: 14-17. [ka]
[0100] In some embodiments, the 2A polypeptide is a variant of the 2A polypeptide disclosed herein. A variant may include a polypeptide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a wild-type or modified 2A polypeptide disclosed herein. A variant may include, for example, a 2A polypeptide of any one of SEQ ID NOs: 14-21, with at least one N-terminal amino acid deleted, for example, one, two, three, four, or five amino acids deleted (including the range between any two of the enumerated values). A variant may include a 2A polypeptide of any one of SEQ ID NOs: 14-21, with at least one C-terminal amino acid deleted, for example, one, two, three, four, or five amino acids deleted (including the range between any two of the enumerated values). A variant may also contain at least one, two, three, four, or five amino acid substitutions, eg, conservative amino acid substitutions.
[0101] VI. Pharmaceutical Compositions Compositions comprising recombinant adenovirus or recombinant adenovirus genomes are provided herein. The compositions are optionally suitable for in vitro or in vivo formulation and administration. Optionally, the compositions comprise one or more of the provided agents and a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy, 22nd Edition, edited by Loyd V. Allen et al., Pharmaceutical Press (2012). Pharmaceutically acceptable carriers include: The term "carrier" includes materials that are not biologically or otherwise undesirable. That is, the material is administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with other components in the pharmaceutical composition in which it is contained. When administered to a subject, the carrier is optionally selected to minimize degradation of the active ingredient and to minimize deleterious side effects in the subject.
[0102] The recombinant virus (or one or more nucleic acids or vectors encoding the recombinant adenovirus) are administered according to known methods, for example, intravenously, e.g., by bolus or continuous infusion over an extended period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, intratumoral, or inhalation routes. Administration may be local or systemic. The compositions may be administered topically, orally, parenterally, intravenously, intra-articular, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermal, or intradermal routes. The compositions can be administered via any of several routes of administration, including intrahepatic, intracranial, nebulized / inhaled, or via placement via a bronchoscope. Thus, the compositions are administered in a number of ways, depending on whether local or systemic treatment is desired and on the area to be treated.
[0103] In some embodiments, the composition for administration comprises the recombinant adenovirus (or recombinant genome) described herein dissolved in a pharma- ceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, such as buffered saline. These solutions are sterile and usually free of undesirable substances. These compositions can be sterilized by conventional, well-known sterilization techniques. The composition may contain pharma- cetically acceptable auxiliary substances, such as pH adjusting and buffering agents, toxicity adjusting agents, etc., as necessary to approximate physiological conditions, such as sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The concentration of active agent in these formulations can vary widely and will be selected primarily based on the volume, viscosity, weight, etc. of fluid, depending on the specific mode of administration selected and the needs of the subject.
[0104] Pharmaceutical formulations, particularly pharmaceutical formulations of recombinant viruses, can be prepared by mixing a recombinant adenovirus (or one or more nucleic acids encoding the recombinant adenovirus) having a desired degree of purity with optional pharma- ceutically acceptable carriers, excipients, or stabilizers. Such formulations can be lyophilized formulations or aqueous solutions.
[0105] Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosage and concentration used.Acceptable carriers, excipients, or stabilizers can be acetates, phosphates, citrates, and other organic acids; antioxidants (e.g., ascorbic acid), preservatives, low molecular weight polypeptides; proteins, such as serum albumin or gelatin, or hydrophilic polymers, such as polyvinylpyrrolidone; and amino acids, monosaccharides, disaccharides, and other carbohydrates, such as glucose, mannose, or dextrin; chelating agents; and ionic and nonionic surfactants (e.g., polysorbates); salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants.Recombinant adenovirus (or one or more nucleic acids encoding recombinant adenovirus) can be formulated in any suitable concentration of infectious unit.
[0106] Formulations suitable for oral administration can consist of (a) a liquid solution, e.g., an effective amount of the recombinant adenovirus suspended in a diluent, e.g., water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient as a liquid, solid, granules, or gelatin; (c) a suspension in a suitable liquid; and (d) a suitable emulsion. Tablet forms may contain lactose, sucrose, mannitol, sorbitol, calcium phosphate, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffers, moistening agents, preservatives, flavorings, dyes, disintegrants, and pharma- ceutically compatible carriers. Lozenge forms may contain the active ingredient in a flavoring, such as sucrose, as well as pastilles containing the active ingredient in an inert base, such as an emulsion of gelatin and glycerin or sucrose and acacia, gels, and the like, which contain, in addition to the active ingredient, carriers known in the art.
[0107] The recombinant adenovirus (or one or more nucleic acids encoding the recombinant adenovirus), alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation. The aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
[0108] Suitable formulations for parenteral administration, for example, by intra-articular (into joint), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous isotonic sterile injection solutions (which may contain antioxidants, buffers, bacteriostatic agents, and solutes to make the formulation isotonic with the blood of the intended recipient), and aqueous and non-aqueous sterile suspensions that may contain suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.In the provided method, the composition can be administered, for example, by intravenous injection, orally, topically, intraperitoneally, intravesically, intratumorally, or intrathecally.Parenteral, intratumoral, and intravenous administration are the preferred methods of administration.The formulations of the compound can be presented in single-dose or multi-dose sealed containers, for example, ampoules and vials.
[0109] Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced or infected with adenovirus, or, for ex vivo therapy, transfected with nucleic acid, can also be administered intravenously or parenterally as described above.
[0110] In some embodiments, pharmaceutical preparations are in unit dosage form.In such form, preparations are divided into unit doses that contain appropriate amounts of active components.Therefore, pharmaceutical compositions can be administered in various unit dosage forms according to the method of administration.For example, the unit dosage forms suitable for oral administration include, but are not limited to, powder, tablet, pill, capsule, and lozenge.
[0111] VII. Methods of Treatment The recombinant adenovirus, recombinant adenovirus genome, and composition disclosed herein can be administered for therapeutic or prophylactic treatment. Specifically, methods are provided for reducing or inhibiting the viability or proliferation of tumor cells in a subject, reducing or inhibiting the progression of tumors in a subject, reducing the number of metastases, reducing the size and / or volume of metastases, reducing the size and / or volume of tumors in a subject, and / or treating cancer in a subject. The method comprises administering a therapeutically effective amount of a recombinant adenovirus or recombinant adenovirus genome (or a composition thereof) to the subject. As described throughout, the adenovirus or pharmaceutical composition is administered in any of a number of ways, including but not limited to intravenously, intravascularly, intrathecally, intramuscularly, subcutaneously, intratumorally, intraperitoneally, or orally. Optionally, the method further comprises administering one or more additional therapeutic agents, such as chemotherapeutic agents, biologics, and / or radiation, to the subject.
[0112] In some embodiments, the cancer or tumor is a lung, prostate, colorectal, breast, thyroid, kidney, pancreas, bone, head and neck, or liver cancer or tumor, or is a type of leukemia. In some cases, the cancer is metastatic. In some embodiments, the tumor is a breast, pituitary, thyroid, or prostate tumor; a brain, liver, meningeal, bone, ovarian, uterine, or cervix tumor; a monocytic or myeloid leukemia; an adenocarcinoma, an adenoma, an astrocytoma, a bladder tumor, a brain tumor, a Burkitt's lymphoma, a breast cancer, a cervical cancer, a colon cancer, a kidney cancer, a liver cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a rectal cancer, a skin cancer, a stomach cancer, a testicular cancer, a thyroid cancer, a chondrosarcoma, a choriocarcinoma, a fibroma, a fibrosarcoma, a glioblastoma, a glioma, a hepatoma, a histiocytoma, a leiomyoblastoma, a leiomyosarcoma, a lymphoma, a liposarcoma cell, a breast tumor, a medulloblastoma, a myeloma, a plasma cell The tumor is selected from the group consisting of sarcoma, neuroblastoma, glioma, osteogenic sarcoma, pancreatic tumor, pituitary tumor, retinoblastoma, rhabdomyosarcoma, sarcoma, testicular tumor, thymoma, and Wilms' tumor. Tumors include both primary and metastatic solid tumors, including carcinomas of the breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder, and urothelium), female reproductive tract (including cervix, uterus, and ovaries, and choriocarcinoma and gestational trophoblastic disease), male reproductive tract (including prostate, seminal vesicles, testes, and germ cell tumors), endocrine glands (including thyroid, adrenal, and pituitary gland), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissue, and Kaposi's sarcoma), and tumors of the brain, nerves, eyes, and meninges (including astrocytoma, glioma, glioblastoma, retinoblastoma, neuroma, neuroblastoma, neurinoma, and meningioma). In some embodiments, solid tumors arising from hematopoietic malignancies such as leukemia (i.e., chloroma, plasmacytoma, and mycosis fungoides plaques and tumors, and cutaneous T-cell lymphoma / leukemia), as well as solid tumors arising in the treatment of lymphomas (both Hodgkin's lymphoma and non-Hodgkin's lymphoma) can be treated.In addition, treatment can be useful in preventing metastasis from the tumors described herein.
[0113] In therapeutic applications, recombinant adenovirus or compositions thereof are administered to a subject in a therapeutically effective amount or therapeutically effective dose. The amount effective for this use will depend on the severity of the disease and the general health of the patient. Single or multiple administrations of the composition can be administered, depending on the dosage and frequency required and tolerated by the patient. "Patient" or "subject" includes both humans and other animals, particularly mammals. Thus, the method is applicable to both human therapy and veterinary applications, such as mice, rats, rabbits, cats, dogs, cows, horses, pigs, chickens, etc.
[0114] The effective amount of adenovirus having a modified sequence will be determined for each individual and will depend, at least in part, on the particular recombinant adenovirus used, the size, age, and sex of the individual, as well as the size and other characteristics of the growing cells. For example, for human treatment, it is recommended to administer at least 10 3 Plaque forming units (PFU) of recombinant virus are used, e.g., at least 10 depending on the type, size, and number of proliferating cells or neoplasms present. 4 , at least 10 5 , at least 10 6 , at least 10 7 , at least 10 8 , at least 10 9 , at least 10 10 , at least 10 11 , or at least 10 12 PFU, e.g., about 10 3 ~10 12 PFU of the recombinant virus is used. The effective amount is about 1.0 pfu / kg body weight to about 10 15 pfu / kg body weight (e.g., about 10 2 pfu / kg body weight ~ approx. 10 13 The recombinant adenovirus may be administered in a single dose or in multiple doses (e.g., 2, 3, 4, 6 or more doses). The multiple doses may be administered simultaneously or sequentially (e.g., over a period of days or weeks).
[0115] In some embodiments, the methods provided include administering to the subject one or more additional therapeutic agents, e.g., anti-cancer agents or other therapeutic treatments (such as surgical removal of a tumor). Exemplary anti-cancer agents include chemotherapeutic agents, e.g., mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, and the like. These include, but are not limited to, agents, enzymes, topoisomerase inhibitors, anti-survival agents, biological response modifiers, anti-hormonal agents (e.g., anti-androgens), anti-angiogenic agents, and CDK inhibitors. Other anti-cancer treatments include radiation therapy and other antibodies that specifically target cancer cells.
[0116] Non-limiting examples of alkylating agents include nitrogen mustards (such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard, or chlorambucil), alkylsulfonates (such as busulfan), nitrosoureas (such as carmustine, lomustine, semustine, streptozocin, or dacarbazine).
[0117] Non-limiting examples of antimetabolites include folic acid analogs (such as methotrexate), pyrimidine analogs (such as 5-FU or cytarabine), and purine analogs, such as mercaptopurine or thioguanine.
[0118] Non-limiting examples of natural products include vinca alkaloids (such as vinblastine, vincristine, or vindesine), epipodophyllotoxins (such as etoposide or teniposide), antibiotics (such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or mitomycin C), and enzymes (such as L-asparaginase).
[0119] Non-limiting examples of other agents include platinum coordination complexes (such as cis-diamine-dichloroplatinum II, also known as cisplatin), substituted ureas (such as hydroxyurea), methylhydrazine derivatives (such as procarbazine), and adrenal cortical suppressants (such as mitotane and aminoglutethimide).
[0120] Non-limiting examples of hormones and antagonists include corticosteroids (such as prednisone), progestins (such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrolacetate), estrogens, (such as diethylstilbestrol and ethinyl estradiol), antiestrogens (such as tamoxifen), and androgens (such as testosterone propionate and fluoxymesterone).
[0121] Examples of the most commonly used chemotherapy drugs include Adriamycin, Alkeran, Ara-C, BiCNU, Busulfan, CCNU, Carboplatin ), Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU , Fludarabine, Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin, Mitoxantrone, Nitrogen Mustard, Taxol (or other taxanes, e.g., Docetaxel), Velban, Vincristine, VP-16, but some newer drugs include Gemcitabine (Gemzar), Herceptin, Irinotecan (Camptosar, CPT-11), Leustatin, Navelbine, Rituxan STI-571, Taxotere, Topotecan (Hycamtin), Xeloda (Capecitabine), Zevelin, and Calcitriol. Examples include
[0122] Non-limiting examples of immune modulators that can be used include AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (granulocyte-macrophage colony-stimulating factor, Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immunoglobulin (Cutter Biological), IMREG (from Imreg, New Orleans, La.), SK&F 106528, and TNF (tumor necrosis factor, Genentech).
[0123] CDK (cyclin-dependent kinase) inhibitor is a drug that inhibits the function of CDK.Non-limiting examples of CDK inhibitor for use in provided method include AG-024322, AT7519, AZD5438, flavopiridol, indisulam, P1446A-05, PD-0332991 and P276-00 (see, for example, Lapenna et al., NatureReviews, vol. 8, pp. 547-566, 2009). Other CDK inhibitors include LY2835219, palbociclib, LEE011 (Novartis), the pan-CDK inhibitor AT7519, seliciclib, CYC065, butyrolactone I, hymenialdisine, SU9516, CINK4, PD0183812, or fascaplysin.
[0124] In some embodiments, the CDK inhibitor is a broad-spectrum inhibitor (such as flavopiridol, olomoucine, roscovitine, kenpaullone, SNS-032, AT7519, AG-024322, (S)-roscovitine, or R547). In other embodiments, the CDK inhibitor is a specific inhibitor (such as fascaplysin, ryuvidine, purvalanol A, NU2058, BML-259, SU 9516, PD0332991, or or P-276-00, etc.
[0125] In some embodiments, the methods provided further comprise administering to the subject a therapeutically effective amount of an immunotherapy.Non-limiting examples of immunomodulatory factors that can be used include AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (granulocyte macrophage colony stimulating factor, Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immunoglobulin (Cutter Biological), IMREG (from Imreg, New Orleans, La.), SK&F 106528, and TNF (tumor necrosis factor, Genentech). The immunotherapeutic agent may be a PD-1 or PD-L1 antagonist, such as an antibody that specifically binds to PD-1 or PD-L1, such as atezolizumab, MPDL3280A, BNS-936558 (nivolumab), pembrolizumab, pidilizumab, CT011, AMP-224, AMP-514, MEDI-0680, BMS-936559, BMS935559, MEDI-4736, MPDL-3280A, MSB-0010718C. The immunotherapeutic agent may also be a CTLA-4, LAG-3, or B7-H3 antagonist, such as tremelimumab, BMS-986016, and MGA271.
[0126] In some embodiments, the provided method further comprises administering to the subject a therapeutically effective amount of one or more antiangiogenic agents, such as proteins, enzymes, polysaccharides, oligonucleotides, DNA, RNA, and recombinant vectors, and small molecules, that function to reduce or even inhibit the growth of blood vessels. Examples of suitable angiogenesis inhibitors include, but are not limited to, angiostatin K1-3, staurosporine, genistein, fumagillin, medroxyprogesterone, suramin, interferon-alpha, metalloproteinase inhibitors, platelet factor 4, somatostatin, thrombospondin, endostatin, thalidomide, and derivatives and analogs thereof. For example, in some embodiments, the antiangiogenic agent is an antibody that specifically binds to VEGF (e.g., AVASTIN®, Roche) or an antibody that specifically binds to a VEGF receptor (e.g., VEGFR2 antibody). In one example, the antiangiogenic agent includes a VEGFR2 antibody or DMXAA (also known as vadimezan or ASA404, commercially available, e.g., from Sigma Corp., St. Louis, Mo.), or both. The antiangiogenic agent can be bevacizumab, sunitinib, an antiangiogenic tyrosine kinase inhibitor (TKI), e.g., sunitinib, xitinib, and dasatinib. These may be used individually or in any combination.
[0127] In some embodiments, the provided method further comprises administering to the subject a therapeutically effective amount of one or more kinase inhibitors that prevent phosphorylation and activation of growth factors, such as GLEEVAC®, IRESSA®, and TARCEVA®, sunitinib, sorafenib, anitinib, and dasatinib. Antibodies that can be used include HERCEPTIN® and AVASTIN®, which block growth factor and angiogenesis pathways. These can be used individually or in combination.
[0128] In some embodiments, provided methods include administering to a subject a therapeutically effective amount of one or more therapeutic monoclonal antibodies, such as, for example, 3F8, Abagovomab, Adecatumumab, Afutuzumab, Alacizumab, Alemtuzumab, Altumomabpentetate, Anatumomabmafenatox, Apolizumab, Arcitumomab, Bavituximab, Bectumomab, Belimumab, Beziresomab, Bevacizumab, Bivatuzumabmertansine, Blinatumomab, Brentuximab ... Ximab vedotin, Cantuzumab mertansine, Capromab pendetide, Catumaxomab, CC49, Cetuximab, Citatuzumab bogatox, Cixutumumab, Clivatuzumab tetraxetan, Conatumumab, Dacetuzumab, Detumomab, Ecromeximab, Eculizumab, Edrecolomab, Epratuzumab, Ertumaxomab, Etaraxiz Mab, Farletuzumab, Figitumumab, Galixirin Mab, Gemtuzumab ozogamicin, Girentuximab, Glembatumumab vedotin, Ibritumomab tiuxetan, Igovomab, Imciromab, Intetumumab, Inotuzumab ozogamicin , Ipilimumab, Iratumumab, Labetuzumab, Lexatumumab, Lintuzumab, Lorvotuzumabmertansine, Lucatumumab, Rumiliximab, Mapatumumab, Matuzumab, Mepolizumab, Metelimumab (Metelimumab), Milatuzumab, Mitumomab, Morolimumab, Nacolomabtafenatox, Naptumomab estafenate necitumumab, nimotuzumab, nofetumomab merpentane, Fatumumab, Olaratumab, Oportuzumabmonatox, Oregovomab, Panitumumab, Pemtumomab, Pertuzumab, Pintumomab, Pritumumab, Ramucirumab, Rilotumumab, Rituximab, Lobatumumab (Robatumumab), Satumomab pendetide, Sibrotuzumab, Sonepcizumab, Tacatuzumab tetraxetan, Taplitumomab paptox, Tenatumomab, TGN1412, Ticilimumab (Tremelimumab ), Tigatuzumab, TNX-650, Trastuzumab, Tremelimumab In some embodiments, the heterologous ORF encodes one of these therapeutic antibodies.
[0129] Another common treatment for some types of cancer is surgery, such as surgical removal of the cancer or a portion thereof. Another example of a treatment is radiation therapy, such as administering radioactive material or energy (such as external beam light therapy) to the tumor site to eradicate the tumor or help it shrink before surgical removal.
[0130] The choice of agent and dosage can be easily determined by those skilled in the art based on the given disease being treated.The combination of agents or compositions can be administered either in parallel (e.g., as one mixture), separately but simultaneously (e.g., through separate intravenous lines), or sequentially (e.g., one agent is administered first, followed by the second agent).Thus, the term combination is used to refer to the parallel, simultaneous, or sequential administration of two or more agents or compositions.
[0131] According to the methods disclosed herein, a subject is administered an effective amount of one or more of the agents provided herein. An effective amount is defined as any amount necessary to produce a desired physiological response (e.g., killing of cancer cells). The therapeutic agent is typically administered at an initial dosage of about 0.001 mg / kg to about 1000 mg / kg per day. Dose ranges of about 0.01 mg / kg to about 500 mg / kg, or about 0.1 mg / kg to about 200 mg / kg, or about 1 mg / kg to about 100 mg / kg, or about 10 mg / kg to about 50 mg / kg can be used. Dosages, however, may vary depending on the requirements of the subject, the severity of the condition being treated, and the compound being used. For example, dosages may be empirically determined taking into account the type and stage of cancer diagnosed in a particular subject. The dosage administered to a subject, in the context of the methods provided, shall be sufficient to produce a beneficial therapeutic response in the patient over time. Determining the proper dosage for a particular situation is within the skill of a person skilled in the art. Thus, the effective amount and schedule for administering the agent can be empirically determined by a person skilled in the art. The dosage should not be so large as to cause substantial adverse side effects, such as undesirable cross-reactions, anaphylactic reactions, etc. The dosage can be adjusted by the individual physician in the event of any contraindications. Guidance on the appropriate dosage of a given class of pharmaceutical agent can be found in the literature.
[0132] Provided herein is a method for inhibiting the viability or proliferation of tumor cells by contacting tumor cells with recombinant adenovirus, recombinant adenovirus genome, or composition disclosed herein.In some embodiments, the method is an in vitro method.In other embodiments, the method is an in vivo method, and contacting tumor cells comprises administering recombinant adenovirus, recombinant adenovirus genome, or composition to a subject having a tumor.
[0133] Further provided is a method of inhibiting tumor progression or reducing tumor volume in a subject by administering to the subject a therapeutically effective amount of a recombinant adenovirus or recombinant adenoviral genome (or a composition thereof) disclosed herein.
[0134] Also provided are methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of a recombinant adenovirus or recombinant adenoviral genome (or composition thereof) disclosed herein.
[0135] VIII. Adsembly and AdSLIC The adenovirus genome is organized into several functional groups, labeled E1, E2, E3, E4, and L1-5. The E1 region encodes proteins that regulate the transcription of all other viral genes and induce the S phase in the host cell. The E2 region encodes proteins that drive viral DNA replication. The proteins of the E3 region modulate the immune response of the host cell and are nonessential in cell culture. The E4 region contains genes with different functions. And the L1-5 region encodes structural proteins of the viral particle.
[0136] Taking advantage of this natural segregation of functionality, we have previously developed a method of recombinant adenovirus assembly that allows for rapid and easy manipulation of the 36 kb Ad genome by separating it into four plasmids: E1, E3, E4, and core, as shown in Figure 6A (Adsembly and AdSLIC, see WO 2012 / 024351, which is incorporated herein by reference). Due to their more reasonable size, these smaller plasmids are easier to manipulate using standard techniques.
[0137] Adsembly and AdSLIC allow the in vitro combinatorial assembly of adenoviruses with novel properties from compatible genomic library parts in 4 hours. Adsembly and AdSLIC provide a general genome design platform that allows the assembly of synthetic viruses with novel properties using a library of four functional parts (Figure 6A). These libraries of parts can be reassembled in all possible combinations using either multiple site-specific recombination sites (Adsembly, Figure 6B) or sequence-independent seamless cloning (AdSLIC, Figure 6C).
[0138] Adsembly and AdSLIC technologies enable modular design and production of adenoviruses with unique capabilities. Developing the ability to design, manufacture, and test viruses in an automated, high-throughput manner will accelerate and scale the development of new viruses for therapeutic, diagnostic, and research studies.
[0139] The cloning step was once an obstacle to the production of new viral constructs, but with the advent of Adsembly and AdSLIC, the ability to assemble viral genomes has surpassed the ability to test them. Comparably, high-throughput kinetic assays are crucial to unlock the full potential and high-content assemblies of synthetic personalized viral therapeutics and diagnostics using the Adsembly and AdSLIC methods.
[0140] The following examples are provided to illustrate certain specific features and / or embodiments, and are not to be construed as limiting the disclosure to the specific features or embodiments described. EXAMPLES
[0141] Example 1: Identification of the optimal location of an exogenous ORF in the adenovirus genome This example describes the identification of specific locations within the adenovirus genome where an exogenous ORF can be inserted along with a self-cleaving peptide sequence without disrupting viral dynamics.
[0142] The insertion of exogenous genes into adenovirus vectors is limited by the size capacity of adenovirus capsid. Excessive addition of exogenous nucleic acid leads to incomplete genome loading into capsid and reduces virus kinetics. The solution to the problem presented by the limited space available in the adenovirus genome is to position an exogenous open reading frame (ORF) as a fusion product within the original adenovirus ORF. This strategy utilizes the adenovirus promoter, 5'UTR and polyA tail already encoded in the genome. However, the expression of a fusion between an original adenovirus protein and an exogenous protein may be detrimental to one or both protein functions, resulting in a significant decrease in adenovirus replication kinetics. Indeed, the studies disclosed herein demonstrate that direct fusion of an exogenous ORF to the ORF of adenovirus E1A, DNA polymerase, or ADP significantly inhibits adenovirus replication kinetics. In addition, we have previously attempted to insert exogenous ORFs using an internal ribosome entry site (IRES), but this has also failed to produce recombinant viruses with wild-type kinetics.
[0143] In this example, a solution to this problem is described by using a self-cleaving peptide sequence that is placed between native adenovirus ORF and exogenous ORF.When placed between two ORFs on a single mRNA, the presence of the self-cleaving peptide sequence causes ribosome skipping, and the first protein is released separately from the second protein.The adenovirus construct generated in this example uses the self-cleaving peptide P2A and a fluorescent protein (e.g., YPet, mCherry) as a heterologous ORF.
[0144] The table below provides a list of the constructs generated and shows the expression levels (low, moderate, or high) of the exogenous ORF and the viral replication kinetics (low, moderate, or high) in two different cell lines (293-E4 cells and A549 cells). [Table 2]
[0145] Constructs exhibiting "high" replication kinetics (i.e., replication kinetics comparable to wild-type adenovirus) in both cell types are considered candidates for generating therapeutic adenovirus constructs (shown in bold). In addition, fiber-P2A-heterologous ORF constructs exhibited significant defects in viral replication but resulted in extremely high levels of heterologous protein expression. Thus, these fiber constructs can also be used in therapeutic applications for the production of high levels of therapeutic proteins in the context of recombinant defective adenoviruses.
[0146] Comparison of direct fusion and P2A site insertion Several constructs were generated in which fluorescent proteins were directly fused to the adenovirus ORF, specifically the following direct fusions were generated: YPet-E1A, YPet (DNA polymerase), and mCherry-ADP.
[0147] YPet-E1A adenovirus exhibited significant impairment in viral kinetics. Inserting a P2A site between YPet and E1A (YPet-P2A-E1A) improved viral kinetics, but did not restore viral kinetics to wild-type levels. Another construct was then generated to test the fusion of P2A and YPet to the C-terminus of E1A (E1A-P2A-YPet). This construct further improved viral kinetics, but again did not restore kinetics to the level of wild-type adenovirus.
[0148] Several attempts to transfect the YPet-(DNA-poly) genomic plasmid failed to produce viable virus (no plaques were formed). However, fusing YPet-P2A to the N-terminus of DNA polymerase (YPet-P2A-(DNA-poly)) produced virus with wild-type kinetics, as shown in the table above.
[0149] In addition, direct fusion of mCherry to ADP (mCherry-ADP) produced viruses with significantly impaired kinetics. However, insertion of a P2A site between the mCherry and ADP ORFs yielded viruses with wild-type kinetics (mCherry-P2A-ADP). The same results were obtained using a different fluorescent protein, with the YPet-P2A-ADP construct exhibiting wild-type virus kinetics. However, placing P2A and a heterologous ORF C-terminal to ADP produced viruses that did not replicate. Thus, for ADP, the heterologous ORF must be placed at the N-terminus.
[0150] Both direct fusion to fiber and insertion of a P2A site between fiber and the heterologous ORF produced viruses with significantly impaired replication kinetics, however, recombinant adenoviruses containing the fiber-P2A-heterologous ORF exhibited extremely high expression levels of the heterologous protein (in this example, YPet or blue fluorescent protein (BFP)).
[0151] Additional constructs with wild-type viral kinetics Figure 7 shows a comparison of the natural log slopes of six different constructs: YPet-E1A, YPet-P2A-E1A, E1A-P2A-mCherry, E1B-55k-P2A-YPet, YPet-P2A-ADP, and fiber-P2A-YPet. As mentioned above, direct fusion of YPet to E1A produced viruses with significantly impaired kinetics, and addition of a P2A site to either the N-terminus (YPet-P2A-E1A) or C-terminus (E1A-P2A-mCherry) improved viral kinetics, but not to wild-type levels. However, insertion of a P2A site and a heterologous ORF into the C-terminus of E1B-55k (E1B-55k-P2A-YPet) or the N-terminus of ADP (YPet-P2A-ADP) produced recombinant viruses with wild-type viral kinetics.
[0152] Assessment of the viral kinetics of constructs with a P2A site and a heterologous ORF at the C-terminus of DBP (DBP-P2A-YPet) or E3-14.7k (E3-14.7k-P2A-YPet), or with a P2A site and a heterologous ORF at the N-terminus of E4-ORF2 (YPet-P2A-E4-ORF2 and mCherry-P2A-E4-ORF2), yielded viruses with wild-type replication kinetics.
[0153] The results of these data indicate that at least the following adenoviral genome constructs can be used to develop therapeutic adenoviral constructs: E1B-55k-P2A-Heterogeneous ORF Heterologous ORF-P2A-(DNA polymerase) DBP-SC-heterogeneous ORF Heterogeneous ORF-SC-ADP E3-14.7k-SC-Heterogeneous ORF Heterogeneous ORF-P2A-E4-ORF2 Fiber-P2A-heterologous ORF
[0154] For therapeutic applications, the heterologous ORF encodes a therapeutic protein.
[0155] Other adenovirus serotypes All previously described methods for measuring viral kinetics are highly dependent on cell type specific assays and are therefore serotype specific due to the diverse tropism of each adenovirus serotype. The adenovirus kinetics assay disclosed herein is not dependent on any one cell type and therefore can be extended to serotypes other than Ad5. All adenovirus serotypes contain ORFs equivalent to Ad5 E3-14.7k. Thus, Ad9 (containing E3-15k) and Ad34 (containing E3-14.8k) were used to generate viruses equivalent to Ad5 E3-14.7k-P2A-YPet (PCMN-887, SEQ ID NO: 9): PCMN-888 (Ad9 E3-15k-P2A-YPet, SEQ ID NO: 22) and PCMN-889 (Ad34 E3-14.8k-P2A-YPet, SEQ ID NO: 23). Chimeric viruses containing the Ad5 core and fiber shaft and knob from either Ad9 or Ad34 were also generated. The four recombinant viruses were then tested in FBVK assays using 293 cells (Figure 9A), A549 cells (Figure 9B), and U2OS cells (Figure 9C). All four recombinant viruses exhibited high levels of YPet expression, and the insertion of the exogenous ORF caused minimal effects on viral dynamics.
[0156] Example 2: Methods for assessing adenovirus replication kinetics The Adsembly and AdSLIC methods for assembling recombinant adenoviruses provide a means to generate large numbers of recombinant viral genomes and viruses in a short time. However, there is a need for a fast and high-throughput method to evaluate the replication kinetics of recombinant adenoviruses designed for clinical and therapeutic use. In this example, we describe a fluorescence-based viral kinetics assay that can be used to test the viral replication kinetics of recombinant adenoviruses (Figure 3). This assay can be performed using either recombinant adenovirus genome plasmids or recombinant adenovirus particles as starting materials.
[0157] When starting with a recombinant adenoviral genome, the assay involves transfecting cells with an adenoviral genome plasmid (such as those described above in Example 1) and monitoring the expression of a fluorophore over time (Figures 4A-4B). Transfection conditions are chosen such that approximately 5-10% of the cells are transfected the first time. Cells not transfected the first time are available for secondary infection with viral particles produced by the first transfection. The logarithmic slope is used as a measure of kinetics based on secondary, tertiary, and quaternary infections (etc.), so it is not necessary to know the percentage of cells transfected the first time. Figures 4A and 4B show an exemplary virus-based kinetic assay starting with a recombinant adenoviral genome plasmid. In this example, a 48-well plate is used, which allows 14 different viral constructs to be tested simultaneously (in triplicate). The top half of the 48-well plate (Figure 4A) contains six different viruses, three mock-infected wells, and three "blank" wells with FLUORESBRITE™ beads to compensate for tool sensitivity variation. The bottom half of the 48-well plate (Figure 4B) contains triplicate wells of eight different viral constructs. Once the cells are transfected, the plate is placed in a TECAN™ plate reader for continuous fluorescence monitoring. The collected data is used to calculate the natural log slope of each construct (Figure 8).
[0158] This assay can also be performed by infecting cells with recombinant viral particles. In this version of the assay, cells are infected with recombinant viral particles and fluorophore expression is monitored over time (Figure 5). As with the genomic plasmid version of the assay, it is not necessary to know the exact titer of the starting viral stock. Typically, a dilution series is used for initial infection, for example, ranging from 1:100 to 1:218,700, as shown in Figure 5. A dilution of 1:100 generally results in infection of all cells, while a dilution of 1:218,700 generally results in initial infection of very few cells. In this example, a 96-well plate is used and 11 different viral constructs are tested simultaneously at eight different dilutions (1:100, 1:300, 1:900, 1:2700, 1:8100, 1:24,300, 1:72,900, and 1:218,700). The plate also contains 4 wells of mock infected cells and 4 wells of FLUORESBRITE™ beads. Once the cells are infected, the plate is placed in a TECAN™ plate reader for continuous fluorescence monitoring. The collected data is used to calculate the natural log slope of each construct (Figure 8).
[0159] The TECAN™ plate reader also provides incubation capabilities (maintaining appropriate temperature, and CO2 and O2 levels). Data points are acquired every 15 minutes to calculate the natural log slope. Using these methods, it is possible to quickly and efficiently compare kinetics between many different viruses and different cell types. For example, to evaluate whether a particular recombinant adenovirus can be used therapeutically as an oncolytic virus, this assay can be used to find viruses that exhibit high replication kinetics in tumor cells but slow viral kinetics in non-tumor cells. Furthermore, the viral kinetics of recombinant viruses can be evaluated by infecting or transfecting the tumor cell type of interest in this assay.
[0160] Calculating the logarithmic slope To measure the logarithmic slope, the linear plot of fluorescence intensity versus time is converted to a semi-logarithmic plot by taking the natural logarithm of the fluorescence intensity measured at each time point. Because fluorescence intensity exhibits exponential growth during viral replication, this conversion results in a straight line when the natural logarithm (fluorescence intensity) is plotted against time. This line is then fitted using standard least squares methods. The resulting slope produced by this fit is the natural logarithmic slope of fluorescence versus time, and therefore the natural logarithmic slope of viral growth versus time. The formula is shown below:
number
number
[0161] In view of the numerous possible embodiments to which the principles of this disclosure may be applied, it is to be recognized that the illustrated embodiments are merely examples of the invention and are not to be taken as limiting the scope of the invention, which is rather defined by the following claims, and the inventors therefore claim as their invention all that comes within the scope and spirit of these claims.
Claims
[Claim 1] The invention as depicted in the drawings.
Citation Information
Patent Citations
Exogenous gene expression in therapeutic adenoviruses to minimize effects on viral dynamics
JP7534798B2
Group b adenovirus modified in the e4ORF4 region
WO2015155370A1
